Effects of Lactobacillus acidophilus KBL409 administration on uremic toxins
2024
Kim, M.J. | Jo, M.J. | Park, S.J. | Lee, H.J. | Yu, J.S. | Lee, S.H. | Lee, S.B. | Kim, W.K. | Ko, G.P.
Chronic kidney disease (CKD) is the major global health problem with various adverse health effects including the decrease in kidney functions and the increase in the risk of cardiovascular diseases. Important uremic toxins, such as indoxyl sulfate (IS) and p-Cresyl sulfate (PCS), are produced by the dysbiosis of gut microbiome and can cause kidney injury, osteopenia, neurological damage, and cardiovascular disorder. In this study, we investigated effects and mechanisms of oral administration of Lactobacillus acidophilus (L. acidophilus) KBL409, isolated from feces of healthy Korean male donor, on uremic toxins using the adenine-induced CKD (Ade-CKD) mouse model. Increases in body and kidney weights with the improvement of kidney tissue inflammation were discovered in Ade-CKD mice with L. acidophilus KBL 409. Moreover, IS and PCS in serum or NOX1 and RAGE in kidney, important markers for oxidative stress, were significantly reduced in Ade-CKD mice with L. acidophilus KBL409. Lactobacillus acidophilus KBL409 also significantly increased the antioxidant enzyme HO-1 and the inflammatory signaling marker IκBα and clearly reduced p-p38 and p-ERK, which are significantly increased in Ade-CKD mice. Therefore, we suggest that L. acidophilus KBL409 can improve CKD symptoms via modulations of oxidative stress and inflammatory signaling of the host, followed by the effective reduction of uremic toxins. Lactobacillus acidophilus KBL409 could be used as the novel probiotic approach for prevention or treatment of CKD based on the gut-kidney axis concept.
显示更多 [+] 显示较少 [-]